Talphera, Inc. (TLPH)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on TLPH
With Tiblio's Option Bot, you can configure your own wheel strategy including TLPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLPH
- Rev/Share 0.001
- Book/Share 0.2131
- PB 2.1722
- Debt/Equity 0.0
- CurrentRatio 3.1051
- ROIC -1.0711
- MktCap 9493121.0
- FreeCF/Share -0.5052
- PFCF -0.7154
- PE -1.0446
- Debt/Assets 0.0
- DivYield 0
- ROE -1.2947
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLPH | Rodman & Renshaw | -- | Buy | -- | $4 | Jan. 28, 2025 |
News
About Talphera, Inc. (TLPH)
- IPO Date 2011-02-11
- Website https://talphera.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Vincent J. Angotti
- Employees 13
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.